Dr. Reddy's Starts EUA Process For Russia's Sputnik V COVID-19 Vaccine In India

Dr. Reddy's Laboratories Ltd (NYSE: RDY) has initiated the process with the Drugs Controller General of India for Emergency Use Authorization (EUA) of the human adenoviral vector-based platform COVID-19 vaccine candidate, Sputnik V.
As part of the review process, Dr. Reddy's will present the Phase 2 study's safety profile and interim data of the phase 3 study, which is expected to complete by February 21.
In September last year, Dr. Reddy's partnered with the Russian Direct Investment Fund to conduct Sputnik V's clinical trials and its distribution rights in India.
The vaccine is currently undergoing the Phase 3 trial in India. Interim analysis suggests an efficacy rate of 91.6%, which included data on 19,866 volunteers in Russia who received both the first and second doses of the vaccine.
Sputnik V maintained a consistent efficacy at 91.8%, even among the group of 2,144 volunteers over 60 years old.
Price Action: RDY closed 0.11% higher at $62.72 on Thursday.